Literature DB >> 6861850

Plasma theophylline and caffeine and plasma clearance of theophylline during theophylline treatment in the first year of life.

G Lönnerholm, B Lindström, L Paalzow, G Sedin.   

Abstract

Plasma concentrations of caffeine and theophylline were simultaneously determined in 17 preterm infants after oral administration of aminophylline for treatment of apnoea. The ratio of caffeine/theophylline concentration in plasma increased during the first 2 weeks of treatment, owing to the longer time required for caffeine than for theophylline to reach steady state. The caffeine/theophylline ratio at steady state was 0.57 +/- 0.03 (mean +/- SE). Thus, caffeine contributed significantly to the total methylxanthine load in the infants. The plasma clearance of theophylline was calculated from the plasma steady state concentrations. In 3 preterm infants treated with oral aminophylline, repeated sampling showed an approximately linear increase in clearance with time from 16.8 +/- 0.4 (mean +/- SE) at a postnatal age of 6-11 days to 30.9 +/- 2.5 ml/kg/h at 64-69 days. In 1 full-term infant treated with oral theophylline from 3.5 to 11.5 months of age, the plasma clearance of theophylline increased in a roughly linear manner, reaching a plateau of about 100 ml/kg/h at 6-7 months of age. This corresponds to the clearance found in 1-4 year old infants.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861850     DOI: 10.1007/bf00610057

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Treatment of severe apnea in prematures with orally administered theophylline.

Authors:  R Uauy; D L Shapiro; B Smith; J B Warshaw
Journal:  Pediatrics       Date:  1975-05       Impact factor: 7.124

2.  [Pharmacokinetics of theophylline in low birth weight newborn infants].

Authors:  G Cottancin; P Baltassat; C Bory; M J Challamel; A Frederich
Journal:  Pediatrie       Date:  1977 Oct-Nov

3.  Apnoeic attacks in the newborn treated with aminophylline.

Authors:  J A Kuzemko; J Paala
Journal:  Arch Dis Child       Date:  1973-05       Impact factor: 3.791

4.  Postnatal development of theophylline metabolism in preterm infants.

Authors:  F N Takieddine; K Y Tserng; K C King; S C Kalhan
Journal:  Semin Perinatol       Date:  1981-10       Impact factor: 3.300

5.  Simultaneous determination of theophylline and caffeine after extractive alkylation in small volumes of plasma by gas chromatography--mass spectrometry.

Authors:  S Floberg; B Lindström; G Lönnerholm
Journal:  J Chromatogr       Date:  1980-11-14

6.  Prevention of apnea and bradycardia in low-birthweight infants.

Authors:  D C Shannon; F Gotay; I M Stein; M C Rogers; I D Todres; F M Moylan
Journal:  Pediatrics       Date:  1975-05       Impact factor: 7.124

7.  Theophylline pharmacokinetics in premature infants with apnea.

Authors:  G Giacoia; W J Jusko; J Menke; J R Koup
Journal:  J Pediatr       Date:  1976-11       Impact factor: 4.406

Review 8.  Methylxanthines in apnea of prematurity.

Authors:  J V Aranda; T Turmen
Journal:  Clin Perinatol       Date:  1979-03       Impact factor: 3.430

9.  Plasma xanthine levels in low birthweight infants treated or not treated with theophylline.

Authors:  J L Brazier; H Renaud; B Ribon; B L Salle
Journal:  Arch Dis Child       Date:  1979-03       Impact factor: 3.791

10.  Pharmacokinetic profile of caffeine in the premature newborn infant with apnea.

Authors:  J V Aranda; C E Cook; W Gorman; J M Collinge; P M Loughnan; E W Outerbridge; A Aldridge; A H Neims
Journal:  J Pediatr       Date:  1979-04       Impact factor: 4.406

View more
  2 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  The population pharmacokinetics of theophylline in neonates and young infants.

Authors:  E S Moore; R G Faix; R C Banagale; T H Grasela
Journal:  J Pharmacokinet Biopharm       Date:  1989-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.